Treatment of pustular psoriasis with infliximab.
Pustular psoriasis is a severe form of psoriasis with a generalized pustular eruption. Since TNF-alpha plays an important role in pustular psoriasis, we treated two patients who had not responded to established therapy regimens with the TNF-alpha antagonist infliximab. Both patients showed significant improvements of their skin eruption and their general condition within three days after treatment and without any side effects. We suggest that infliximab is a therapeutic option for severe therapy-resistant pustular psoriasis because a single well-tolerated dose significantly ameliorates the patient's condition.
Weishaupt
Carsten
C
Clinic and Polyclinic for Skin Diseases, Münster University Hospital, Germany.
Metze
Dieter
D
Luger
Thomas A
TA
Ständer
Sonja
S
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D013492:Suppuration / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab